| 摘要 |
Disclosed is the use of a poly (ADP-ribose) polymerase (PARP) inhibitor in the manufacture of a medicament for the treatment of cancer cells defective in homologous recombination, wherein the cancer cells have a defect in a gene which mediates HR, said gene being selected from the group consisting of XRCC1, CTPS, RPA, RPA1, RPA2, RPA3, XPD, ERCC1, XPF, MMS19, RAD51, RAD51B, RAD51C, RAD51D, DMC1, XRCC2, XRCC3, BRCA1, BRCA2, RAD52, RAD54, RAD50, MRE11, NBS1, WRN, BLM, Ku70, Ku80, ATM, ATR, chk1, chk2, FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, RAD1, RAD9, FEN-1, Mus81, Eme1, DDS1 and BARD. |
